Regeneron Pharma’s adjusted earnings beat estimates

📆 2-11-2023 13:01:00
📰 MarketWatch

⏱ Reading Time:
16 sec. here
2 min. at publisher
📊 Quality Score:
News: 10%
Publisher: 97%

Nederland Nieuws Nieuws

Nederland Laatste Nieuws,Nederland Headlines

Steve Gelsi covers banking and cannabis as a Senior Reporter for MarketWatch.

Regeneron Pharmaceuticals Inc.’s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjusted results beat analyst expectations. Regeneron said its third-quarter net income fell 23% to $1 billion, or $8.89 a share, from $1.

32 billion, or $11.66 a share, in the year-ago quarter. Third-quarter adjusted profit rose to $11.59 a share from $11.14 a share in the year-ago period and beat the FactSet consensus estimate of $10.68 a share. Revenue climbed 15% to $3.36 billion, ahead of the Wall Street analyst expectation of $3.23 billion.

Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:

Schrijf commentaar

Nederland Laatste Nieuws, Nederland Headlines

Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.

Ares Acquisition Corp., X-energy scrap $1.8B merger due to ‘persistently volatile public markets’Steve Gelsi covers banking and cannabis as a Senior Reporter for MarketWatch.
Bron: MarketWatch - 🏆 3. / 97 Lees verder »